Chemoradiotherapy for Anal Squamous Cell Carcinoma
Author Information
Author(s): Cho Byoung Chul, Ahn Joong Bae, Seong Jinsil, Roh Jae Kyung, Kim Joo Hang, Chung Hyun Cheol, Sohn Joo Hyuk, Kim Nam Kyu
Primary Institution: Yonsei University College of Medicine
Hypothesis
Does consolidation chemotherapy improve outcomes in patients with anal squamous cell carcinoma treated with chemoradiotherapy?
Conclusion
The study shows that chemoradiotherapy with 5-FU and cisplatin, with or without consolidation chemotherapy, is well tolerated and leads to good long-term survival and anal function preservation.
Supporting Evidence
- Nineteen patients (90.5%) completed all four courses of consolidation chemotherapy.
- After a median follow-up of 72 months, the 5-year overall survival rate was 84.7%.
- 28 patients showed complete responses after chemoradiotherapy.
Takeaway
Doctors treated 31 patients with a combination of chemotherapy and radiation for anal cancer, and most of them did really well, keeping their ability to use the bathroom normally.
Methodology
Patients received chemoradiotherapy with 5-FU and cisplatin, followed by consolidation chemotherapy for those who responded well.
Limitations
The sample size was small, limiting the ability to detect significant differences in outcomes.
Participant Demographics
{"median_age":57,"age_range":"29-75","sex_distribution":{"male":11,"female":20}}
Statistical Information
P-Value
P = 0.465 for overall survival; P = 0.233 for disease-free survival
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website